Global Postpartum Depression Market, By Type (Postpartum Blues, Postpartum Anxiety, Postpartum Obsessive Compulsive Disorder, Postpartum Panic Disorder, Postpartum Post-Traumatic Stress Disorder, Postpartum Psychosis, Others), Treatment (Psychotherapy, Medication, Supplements, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
In recent years, the postpartum depression market is anticipated to grow rapidly during the forecast period. Some women have postpartum depression (PPD) after giving birth to a child. Anxiety, changes in sleeping and eating patterns, melancholy, low energy, and irritability are all common symptoms. PPD usually appears within 4 to 6 weeks of having birth, however it can also arise months later. It does not affect all pregnant women, although it is most common between 3 and 6 months following delivering. This could result in psychological symptoms such as a poor mood that lasts more than a week, sobbing, lack motivation, and a sense of inadequacy. Other variables that contribute to PPD include pregnancy-related physical changes, complicated or difficult labor, loneliness, a history of mental health disorders, and hormone changes.
Data Bridge Market Research analyses that the postpartum depression market was valued at USD 5.115 billion in 2021 and is expected to reach USD 42.37 billion by 2029, registering a CAGR of 30.25% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Postpartum depression (PPD) is a type of depression that occurs after a woman has given birth. The individual who gives birth is not the only one who suffers from postpartum depression. It can also have an impact on surrogates and adoptive parents. After having a baby, people go through hormonal, physical, emotional, economical, and social changes. Symptoms of postpartum depression can arise as a result of these changes.
Report Scope and Market Segmentation
2022 to 2029
2020 (Customizable to 2019 - 2014)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Type (Postpartum Blues, Postpartum Anxiety, Postpartum Obsessive Compulsive Disorder, Postpartum Panic Disorder, Postpartum Post-Traumatic Stress Disorder, Postpartum Psychosis, Others), Treatment (Psychotherapy, Medication, Supplements, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Bayer AG (Germany), Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Eli Lilly and Company (US), Cipla Inc. (US), Aurobindo Pharma (India), Lupin (India), Accord Healthcare (US), Sun Pharmaceutical Industries Ltd. (India), Bausch Health Companies Inc. (Canada), Alvogen (US), Intas Pharmaceuticals Ltd. (India), SHIONOGI & Co., Ltd. (Japan)
Postpartum Depression Market Dynamics
- Rise in the incidences of mood disorders among women
The rising incidences of mood disorders among women is a major factor driving the postpartum depression market's growth rate. After childbirth, the level of hormones in a woman's body fluctuates. The chemical changes caused by the variability in hormone levels lead to mood swings. Constant sleep deprivation is another element that contributes to postpartum depression, however this condition can be cured with adequate rest.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of postpartum depression market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness about the will expand the postpartum depression market. Additionally, high alcohol consumption and changing lifestyle of people will result in the expansion of postpartum depression market. Along with this, rising demand for antidepressant medications and talk therapies will enhance the growth rate of the market.
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the postpartum depression market growth. The rising number of drug approvals and new product launches are the major factors that wil provide new market opportunities in coming years.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the postpartum depression market growth during the forecast period.
On the other hand, high cost of the medication will obstruct the growth rate of market. The dearth of favourable reimbursement policies and low awareness about postpartum depression and its associated complications will pose major challenges to the market’s growth rate. Additionally, the lack of healthcare infrastructure in developing economies and emergence of unfavourable conditions due to COVID-19 pandemic will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This postpartum depression market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the postpartum depression market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
In the United States, roughly 70% to 80% of women will have it in a milder form, whereas 10% to 20% of women may experience it in a severe version. Postpartum depression affects one out of every seven mothers, with an estimated 600,000 instances diagnosed each year in the United States.
Postpartum depression market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Postpartum Depression Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems around the world were severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations had a negative impact on the market of postpartum depression.
- In May 2020, Geisinger had announced the launch of innovative program to screen postpartum depression. The objective of this program is to provide standardized postpartum depression screenings across a woman’s pregnancy journey - from Women’s Health to Pediatrics. It empowers the mothers to thrive psychologically, physically and socially. This program ease the life-challenging as well as thrilling times of women’s life.
Global Postpartum Depression Market Scope
The postpartum depression market is segmented on the basis of type, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Postpartum Blues
- Postpartum Anxiety
- Postpartum Obsessive Compulsive Disorder
- Postpartum Panic Disorder
- Postpartum Post-Traumatic Stress Disorder
- Postpartum Psychosis
- Cognitive Behavioral Therapy
- Interpersonal Therapy
Route of Administration
- Specialty Clinics
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Postpartum Depression Market Regional Analysis/Insights
The postpartum depression market is analysed and market size insights and trends are provided by country, type, treatment, route of administration, end-users and distribution channel as referenced above.
The countries covered in the postpartum depression market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the postpartum depression market because of the growing presence of major key players and rising prevalence of depression among women will further propel the market’s growth rate in this region.
Asia-Pacific are expected to grow during the forecast period of 2022 to 2029 due to growing government initiatives and development of healthcare infrastructure in this region. Also, surging awareness about mood disorders will further propel the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Postpartum Depression Market Share Analysis
The postpartum depression market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to postpartum depression market.
Some of the major players operating in the postpartum depression market are:
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- AstraZeneca (UK)
- Johnson & Johnson Private Limited (US)
- Bayer AG (Germany)
- Merck & Co., Inc. (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Eli Lilly and Company (US)
- Cipla Inc. (US)
- Aurobindo Pharma (India)
- Lupin (India)
- Accord Healthcare (US)
- Sun Pharmaceutical Industries Ltd. (India)
- Bausch Health Companies Inc. (Canada)
- Alvogen (US)
- Intas Pharmaceuticals Ltd. (India)
- SHIONOGI & Co., Ltd. (Japan)